1 – 2 of 2
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
ATOR-4066, a bispecific antibody targeting CD40 and CEACAM5, induces strong myeloid and T cell-dependent tumor immunity and synergizes with PD-1 blockade
(2025) In Cancer immunology research
- Contribution to journal › Article
- 2024
-
Mark
Next-generation CD40 agonists for cancer immunotherapy
- Contribution to journal › Scientific review
